Document is current
Any future updates will be listed below
-
Authors
Titmuss, Emma
Corbett, Richard D.
Davidson, Scott
Abbasi, Sanna
Williamson, Laura M.
Pleasance, Erin D.
Shlien, Adam
Renouf, Daniel J.
Jones, Steven J. M.
Laskin, Janessa
Marra, Marco A. https://orcid.org/0000-0001-7146-7175
-
Funding
Funding for this research was provided by:
Genome British Columbia (B20POG, B20POG, 12002, 12002, 12002)
Genome Canada (202SEQ, 202SEQ, 212SEQ, 212SEQ)
Canada Foundation for Innovation (20070, 20070, 30981, 30981, 30981, 30198, 33408, 33408, 35444)
- License Information
-
More Information
Article History
Received: 4 April 2022
Accepted: 1 September 2022
First Online: 7 September 2022
Declarations
:
: This work, including administrative permissions, was approved by the University of British Columbia BC Cancer Research Ethics Board (H12-00137, H14-00681), and the POG program is registered under clinical trial number NCT02155621. All patients in this study gave informed written consent and were enrolled into POG as described previously [, ].
: Not applicable.
: D.J. Renouf reports grants and personal fees from Roche, as well as personal fees from Bayer, Celgene, Servier, Ipsen, and Taiho outside the submitted work. J. Laskin reports grants to the institution from BC Cancer Foundation and Roche Canada during the conduct of the study; grants from Roche Canada; and personal fees from Roche Canada, Pfizer, Eli Lilly, and Jazz Pharma outside the submitted work. No disclosures were reported by the other authors.
